Mode
Text Size
Log in / Sign up

Case report highlights diagnostic challenges between POEMS syndrome and CIDPMisdiagnosis of rare nerve disorder highlights need for vigilance

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note the potential for POEMS syndrome to be misdiagnosed as CIDP due to overlapping clinical features.

This case report, integrated with a literature review, details the diagnostic trajectory of a single patient presenting with lower limb paresthesia. The patient was initially misdiagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP), but the diagnosis was later clarified as POEMS syndrome through an evaluation of the clinical course, specialized laboratory findings, and histopathological analysis.

The authors discuss the complexities of distinguishing POEMS syndrome from CIDP due to their overlapping neuromuscular presentations. The report notes that the pathogenesis of POEMS syndrome is driven by plasma cell dyscrasias and the dysregulation of VEGF.

A primary limitation of this report is its scope, as it is a case report involving only 1 patient. Because the findings are based on a single case and a literature review, the results may not be generalizable to broader patient populations.

Clinicians should maintain high vigilance when evaluating patients with neuromuscular symptoms. Enhancing diagnostic accuracy requires careful consideration of specialized testing to differentiate POEMS syndrome from CIDP.

It starts with a strange tingling or numbness in your legs. For one patient, this sensation led to a diagnosis of chronic inflammatory demyelinating polyneuropathy, or CIDP. This is a condition where the body's immune system attacks the nerves. While CIDP is serious, it is not the full story for this individual.

After a closer look at the clinical course, specialized lab tests, and tissue analysis, doctors found the real culprit: POEMS syndrome. This is a much rarer and more complex disorder driven by plasma cell dyscrasias, which are abnormal growths of certain blood cells. The syndrome also involves the dysregulation of VEGF, a protein that helps blood vessels grow.

Because the symptoms of POEMS syndrome and CIDP overlap so much, it is easy for even experienced clinicians to miss the distinction. This case report, which includes a review of existing literature, serves as a reminder for doctors to stay alert. Getting the diagnosis right is vital for managing these overlapping neuromuscular issues.

What this means for you:
Doctors must look closely at lab results to tell the difference between CIDP and the rarer POEMS syndrome.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
POEMS syndrome is a rare multisystem disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) secretion, and skin changes. Its pathogenesis is driven by plasma cell dyscrasias and the dysregulation of vascular endothelial growth factor (VEGF). In contrast, chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated condition that primarily affects peripheral nerve myelin, lacking the systemic involvement and hematological markers characteristic of POEMS syndrome. Given their overlapping neuromuscular manifestations—primarily progressive sensory loss and motor weakness—POEMS is frequently misdiagnosed as CIDP during initial presentation. This report presents a case of POEMS syndrome initially presenting with lower limb paresthesia. Through evaluation of the clinical course, specialized laboratory findings, and histopathological analysis, the diagnosis was clarified. By integrating this case with a comprehensive literature review, our study aims to enhance clinical vigilance and diagnostic accuracy in distinguishing POEMS syndrome from CIDP, two disorders with superficially similar neuropathic features but fundamentally different underlying etiologies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.